The shapes, sizes, and content of a US alcoholic drink-equivalent vary widely. Get a quick educational summary of the variety and more data that may help in your daily clinical practice.
All News
Advertisement
Advertisement
Clopidogrel bests aspirin for post-PCI monotherapy; metabolic dysfunction predicts HCC in post-HCV fibrosis; brain signatures may help focus obesity treatment for the sexes, and 2 more studies of note.
Results showed that on average, personalized treatment choice had the potential to provide an additional 4.4 mm Hg-lower systolic blood pressure.
Your daily dose of clinical news you may have missed.
Survey respondents facing the greatest increase in barriers to desired care were aged 25 to 29 years, identified as Hispanic, and lived below 100% of the federal poverty level.
The $462 million monetary penalty is accompanied “the most stringent restrictions” on how the company markets, sells, and distributes its products.
Your daily dose of clinical news you may have missed.
Metabolomic signatures identified in red and processed meat are associated with an increased risk of IHD, according to new findings.
Migraine disproportionately affects women, a disparity typically ascribed to hormonal differences. A new study takes a new look at the issue.
Advertisement
Among other improvements, bariatric surgery may help reverse peripheral neuropathy and stabilize cardiovascular autonomic neuropathy, according to new findings.
Your daily dose of clinical news you may have missed.
Metabolic Dysfunction May Better Predict Risk for HCC in Persons Cured of HCV with Advanced Fibrosis
A population-based study found metabolic dysfunction more prevalent than ultrasonographic steatosis in patients recovered from HCV and a better predictive tool for disease progression.
Your daily dose of clinical news you may have missed.
Updated VA/DoD chronic pain management guidelines include recommendations for dual use of buprenorphine and increased mental health assessment before prescribing opioids.
Ensitrelvir fast track status is supported by phase 3 study findings showing resolution of COVID-19 symptoms a full day earlier in those taking the drug vs placebo.
The FDA, women's health groups and professional societies, and state governors are all pushing back against the April 7 ruling by Texas District Judge Matthew Kacsmaryk.
Your daily dose of clinical news you may have missed.
Recent research shows that patients with mild-to-moderate COVID-19 who received ensitrelvir within 5 days of symptom onset saw their symptoms resolve a day earlier than those who received placebo.
Pain is a prominent symptom among persons with COPD yet management is not included in clinical guidelines and current research findings are vague, say study authors.
Advertisement
Advertisement
Advertisement
